Chiglitazar significantly reduced liver fat content (LFC) in MASH patients, with reductions of 28.1% and 39.5% in the 48mg and 64mg groups, respectively, compared to a 3.2% decrease in the placebo group.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.